Design, synthesis and biological evaluation of novel guanidine-containing matrine derivatives as Topo I/II dual target inhibitors

  • Eur J Med Chem. 2026 Sep 5:313:118884. doi: 10.1016/j.ejmech.2026.118884.
Shihao Li  1 Yu Zhu  2 Yonghui Wang  3 Xuan Liu  3 Zheng Xu  3 Qinghai Dong  3 Shuobing Wang  3 Linlin Cui  3 Chunyan Lv  3 Zhihua Xing  3 Yiru Wang  3 Guanghuan Shen  4 Guoyu Li  5
Affiliations
  • 1. College of Pharmacy, Harbin University of Commerce, Harbin, 150076, PR China. Electronic address: [email protected].
  • 2. College of Pharmacy, Harbin University of Commerce, Harbin, 150076, PR China. Electronic address: [email protected].
  • 3. College of Pharmacy, Harbin University of Commerce, Harbin, 150076, PR China.
  • 4. College of Pharmacy, Harbin University of Commerce, Harbin, 150076, PR China. Electronic address: [email protected].
  • 5. College of Pharmacy, Harbin University of Commerce, Harbin, 150076, PR China. Electronic address: [email protected].
Abstract

Topoisomerase inhibitors are a key focus in the development of antitumor agents. In this work, using matrine as a lead compound, a series of novel derivatives were designed and synthesized as potential dual inhibitors of Topoisomerase I and II (Topo I/II). Among these compounds, A6 and A10 exhibited significant cytotoxicity against MCF-7 cells, with IC50 values of 0.6 μM and 0.7 μM, respectively, comparable to those of the positive controls (CPT, VP-16). Given their superior cytotoxicity and dual Topo I/II inhibitory activity, these two compounds were selected for further pharmacological evaluation. Mechanistic investigations demonstrated that A6 and A10 effectively suppressed the proliferation, invasion, and migration of MCF-7 cells in vitro by inducing DNA damage and activating the mitochondrial apoptotic pathway. Collectively, these findings underscore the potential of A6 and A10 as novel dual Topo I/II inhibitors for Cancer therapy.

Keywords
Antitumor activity; Apoptosis; Dual Topo I/II inhibitors; Matrine derivatives.
Products